Phase 1 Study of Multiple Peptide Vaccine Therapy and GM-CSF in Treating Patients With Esophageal Cancer
LY6K (lymphocyte antigen 6 complex, locus K) was identified as a new target of tumor
associated antigen using cDNA microarray technologies combined with the expression profiles
of normal and cancer tissues. On the other hand, anti-angiogenic therapy is now considered
to be one of promising approaches to treat of cancer. In this clinical trial, we evaluate
the safety and immune responses of multiple peptide cocktail including LY6K and vascular
endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor
receptor 2 (VEGFR2) together with IFA and GM-CSF as immunoadjuvants in patients who had LY6K
expressed primary esophageal cancer. Toxicity profiles will be monitored, and antigen
specific T cell responses will be described.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Toxicity of multiple peptide vaccinations
one year
Yes
Takuya Takayama, M.D.Ph.D
Principal Investigator
Cancer Institute of Japanese Foundation for Cancer Research
Japan: Institutional Review Board
TB-454
NCT00561275
October 2007
June 2008
Name | Location |
---|